Cellectar Biosciences, Inc.(CLRB)Earnings, Financials & Key Ratios
CLRB•NASDAQ
$3.30
$14M mkt cap·Price updated May 7, 2026
AboutCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.Show more
- Revenue$0
- EBITDA-$23M+55.8%
- Net Income-$22M+51.1%
- EPS (Diluted)-8.35+80.1%
- ROE-179.99%+99.0%
- Debt/Equity0.04+19.5%
CLRB Key Insights
Cellectar Biosciences, Inc. (CLRB) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Weak momentum: RS Rating 19 (bottom 19%)
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CLRB Price & Volume
Cellectar Biosciences, Inc. (CLRB) stock price & volume — 10-year historical chart
Loading chart...
CLRB Growth Metrics
Cellectar Biosciences, Inc. (CLRB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM51.12%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM77.27%
Return on Capital
10 Years-507.81%
5 Years-1014.1%
3 Years-1934.32%
Last Year-174.65%
CLRB Peer Comparison
Cellectar Biosciences, Inc. (CLRB) competitors in Radiopharmaceuticals and Targeted Radiation — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 PRTC | 40.96M | 16.97 | -0.37 | -3.5% | -6.25% | -16.12% | 0.06 | |
 RNAC | 216.31M | 8.16 | -1.63 | -92.81% | -85.51% | |||
 RMD | 30.15B | 206.96 | 21.76 | 9.84% | 27.44% | 24.41% | 0.14 | |
 NUVL | 7.53B | 102.40 | -17.50 | -42.78% | ||||
 AGEN | 132.45M | 3.75 | -1102.94 | 10.37% | 0.1% | |||
 MRKR | 24.05M | 1.44 | -1.82 | -46.19% | -999999% | -289.66% | ||
 CLDX | 2.22B | 33.32 | -8.54 | -78.63% | -172.53% | -41.68% | 0.00 | |
 NVS | 277.42B | 145.39 | 20.22 | 5.97% | 24.14% | 31.42% | 0.80 |
Compare CLRB vs Peers
Cellectar Biosciences, Inc. (CLRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CLRB Income Statement
Cellectar Biosciences, Inc. (CLRB) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 1.55M | 82.27K | 189.36K | 0 | 0 | 0 | 0 | 0 | 213.6K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -1.55M▲ 0% | -82.27K▲ 94.7% | -189.36K▼ 130.2% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -213.6K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | -333.47% | 94.68% | -130.18% | 100% | - | - | - | - | - |
| Operating Expenses | 13.6M | 11.66M | 13.99M | 15.29M | 24.13M | 28.81M | 38.96M | 51.78M | 22.77M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 4.14M | 4.82M | 4.99M | 5.15M | 6.54M | 9.59M | 11.69M | 25.64M | 11.48M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 9.47M | 6.84M | 9M | 10.14M | 17.59M | 19.22M | 27.27M | 26.14M | 11.5M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -213.6K |
| Operating Income | -13.6M▲ 0% | -13.33M▲ 2.0% | -14.18M▼ 6.4% | -15.29M▼ 7.8% | -24.13M▼ 57.8% | -28.81M▼ 19.4% | -38.96M▼ 35.2% | -51.78M▼ 32.9% | -22.98M▲ 55.6% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -43.93% | 1.99% | -6.36% | -7.84% | -57.82% | -19.4% | -35.22% | -32.9% | 55.62% |
| EBITDA | -12.05M | -13.25M | -13.99M | -15.08M | -23.98M | -28.67M | -38.77M | -51.49M | -22.77M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -32.57% | -9.9% | -5.59% | -7.81% | -59% | -19.53% | -35.24% | -32.8% | 55.78% |
| D&A (Non-Cash Add-back) | 1.55M | 82.27K | 189.36K | 207.93K | 149.91K | 148.44K | 192.38K | 291.65K | 213.6K |
| EBIT | -13.6M | -13.24M | -14.09M | -15.09M | -24.13M | -28.81M | -38.96M | -51.78M | -22.98M |
| Net Interest Income | 0 | 0 | 42.71K | 10.9K | 2.28K | 152.52K | 387.15K | 1.21M | 435.1K |
| Interest Income | 0 | 0 | 42.71K | 10.9K | 2.28K | 152.52K | 387.15K | 1.21M | 435.1K |
| Interest Expense | 16.61K | 29.69K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 38.68K | -1.58M | 85.71K | 196.18K | 8.92K | -3.04M | -3.87M | 7.26M | 1.19M |
| Pretax Income | -13.56M▲ 0% | -13.24M▲ 2.4% | -14.09M▼ 6.4% | -15.09M▼ 7.1% | -24.12M▼ 59.8% | -31.85M▼ 32.0% | -42.83M▼ 34.5% | -44.52M▼ 3.9% | -21.79M▲ 51.0% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | -60K | -60K | 66K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0.19% | 0.14% | -0.15% | 0% |
| Net Income | -13.56M▲ 0% | -13.24M▲ 2.4% | -14.09M▼ 6.4% | -15.09M▼ 7.1% | -24.12M▼ 59.8% | -31.79M▼ 31.8% | -42.77M▼ 34.5% | -44.58M▼ 4.2% | -21.79M▲ 51.1% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -119.44% | 2.38% | -6.45% | -7.1% | -59.81% | -31.8% | -34.53% | -4.23% | 51.12% |
| Net Income (Continuing) | -13.56M | -13.24M | -14.09M | -15.09M | -24.12M | -31.79M | -42.77M | -44.58M | -21.79M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3210.00▲ 0% | -1567.96▲ 51.2% | -550.86▲ 64.9% | -228.55▲ 58.5% | -130.35▲ 43.0% | -135.18▼ 3.7% | -104.99▲ 22.3% | -41.89▲ 60.1% | -8.35▲ 80.1% |
| EPS Growth % | 50% | 51.15% | 64.87% | 58.51% | 42.97% | -3.7% | 22.33% | 60.1% | 80.07% |
| EPS (Basic) | -3210.00 | -1567.96 | -550.86 | -228.55 | -130.35 | -135.18 | -104.99 | -36.52 | -8.35 |
| Diluted Shares Outstanding | 4.68K | 9.87K | 25.58K | 66.04K | 185.05K | 235.19K | 407.38K | 1.24M | 2.61M |
| Basic Shares Outstanding | 4.68K | 9.87K | 25.58K | 66.04K | 185.05K | 235.19K | 407.38K | 1.22M | 2.61M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
CLRB Balance Sheet
Cellectar Biosciences, Inc. (CLRB) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.47M | 13.95M | 11.39M | 57.94M | 36.57M | 20.53M | 10.45M | 24.25M | 14.04M |
| Cash & Short-Term Investments | 10.01M | 13.26M | 10.61M | 57.17M | 35.7M | 19.87M | 9.56M | 23.29M | 13.2M |
| Cash Only | 10.01M | 13.26M | 10.61M | 57.17M | 35.7M | 19.87M | 9.56M | 23.29M | 13.2M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 55K | 55K | 0 | 0 | 0 | 663.24K | 888.23K | 961.66K | 842.43K |
| Total Non-Current Assets | 1.93M | 1.1M | 865.14K | 719.56K | 630.35K | 1.06M | 1.62M | 1.22M | 939.86K |
| Property, Plant & Equipment | 244.71K | 543.34K | 783.92K | 638.35K | 549.13K | 978.98K | 1.59M | 1.19M | 910.08K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 1.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 11.87K | 558.91K | 81.21K | 81.21K | 81.21K | 81.21K | 29.78K | 29.78K | 29.78K |
| Total Assets | 12.87M▲ 0% | 15.05M▲ 17.0% | 12.25M▼ 18.6% | 58.66M▲ 378.8% | 37.2M▼ 36.6% | 21.59M▼ 42.0% | 12.08M▼ 44.1% | 25.47M▲ 111.0% | 14.98M▼ 41.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | -16.01% | 16.96% | -18.62% | 378.82% | -36.58% | -41.97% | -44.07% | 110.96% | -41.2% |
| Total Current Liabilities | 2.11M | 1.62M | 2.77M | 3.56M | 3.99M | 11.5M | 25.36M | 9.39M | 4.75M |
| Accounts Payable | 1.87M | 1.54M | 1.28M | 1.43M | 1.42M | 2.56M | 5.62M | 4.11M | 1.44M |
| Days Payables Outstanding | 440.95 | 6.85K | 2.46K | - | - | - | - | - | 2.46K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 100.19K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 243.99K | 76.09K | 990.87K | 0 | 1.94M | 7.98M | 17.61M | 4.59M | 3.21M |
| Current Ratio | 4.95x | 8.60x | 4.11x | 16.26x | 9.16x | 1.78x | 0.41x | 2.58x | 2.96x |
| Quick Ratio | 4.95x | 8.60x | 4.11x | 16.26x | 9.16x | 1.78x | 0.41x | 2.58x | 2.96x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 2.21K | 171K | 421.64K | 301.74K | 166.29K | 552.98K | 494K | 1.79M | 309.4K |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 309.4K |
| Capital Lease Obligations | 2.21K | 0 | 421.64K | 301.74K | 166.29K | 552.98K | 494K | 409.59K | 309.4K |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 171K | 0 | 0 | 0 | 0 | 0 | 1.38M | 0 |
| Total Liabilities | 2.12M | 1.79M | 3.19M | 3.86M | 4.16M | 12.05M | 25.85M | 11.18M | 5.06M |
| Total Debt | 5.25K | 2.21K | 527.53K | 421.64K | 301.74K | 603.83K | 552.98K | 494K | 409.59K |
| Net Debt | -10M | -13.25M | -10.09M | -56.74M | -35.4M | -19.26M | -9.01M | -22.79M | -12.79M |
| Debt / Equity | 0.00x | 0.00x | 0.06x | 0.01x | 0.01x | 0.06x | - | 0.03x | 0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -819.09x | -449.04x | - | - | - | - | - | - | - |
| Total Equity | 10.75M▲ 0% | 13.26M▲ 23.3% | 9.06M▼ 31.7% | 54.79M▲ 504.8% | 33.05M▼ 39.7% | 9.54M▼ 71.1% | -13.78M▼ 244.5% | 14.29M▲ 203.8% | 9.92M▼ 30.6% |
| Equity Growth % | -20.57% | 23.31% | -31.68% | 504.84% | -39.69% | -71.14% | -244.48% | 203.76% | -30.61% |
| Book Value per Share | 2299.44 | 1343.15 | 354.12 | 829.69 | 178.57 | 40.54 | -33.82 | 11.55 | 3.80 |
| Total Shareholders' Equity | 10.75M | 13.26M | 9.06M | 54.79M | 33.05M | 9.54M | -13.78M | 14.29M | 9.92M |
| Common Stock | 167 | 47 | 94 | 454 | 611 | 94 | 207 | 461 | 42 |
| Retained Earnings | -84.35M | -97.59M | -111.68M | -126.78M | -150.9M | -159.99M | -202.76M | -247.34M | -269.13M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLRB Cash Flow Statement
Cellectar Biosciences, Inc. (CLRB) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -11.02M | -11.44M | -11.69M | -13.93M | -22.57M | -25.22M | -32.38M | -47.58M | -23.12M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | -33.06% | -3.83% | -2.2% | -19.15% | -61.98% | -11.76% | -28.37% | -46.97% | 51.41% |
| Net Income | -13.56M | -13.24M | -14.09M | -15.09M | -24.12M | -28.6M | -42.77M | -44.58M | -21.79M |
| Depreciation & Amortization | 1.55M | 82.27K | 132.8K | 141.45K | 149.91K | 148.44K | 192.38K | 291.65K | 213.6K |
| Stock-Based Compensation | 758.76K | 721.21K | 866.79K | 467.54K | 1.12M | 1.45M | 2.41M | 4.27M | 2.26M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -22.07K | 1.56M | 13.56K | -118.8K | 80.66K | 93.82K | 4.32M | -5.84M | -677.5K |
| Working Capital Changes | 259.26K | -569.05K | 1.39M | 671.24K | 198.76K | 1.68M | 3.48M | -1.73M | -3.13M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.59M | -3.16M |
| Cash from Investing | -346.7K | -329.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K |
| Capital Expenditures | -346.7K | -384.99K | -24.54K | -62.35K | -141.36K | -225.97K | -864.04K | -104.19K | -5.88K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 55K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 9.93M | 15.02M | 9.02M | 60.55M | 1.25M | 9.61M | 22.94M | 61.41M | 13.03M |
| Debt Issued (Net) | -89.32K | -3.04K | -2.21K | 184K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 1000K | 1000K | 34.87K | 1000K | 1000K | 1000K | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 2.85M | -762 | 0 | 642.5K | 1.21M | -9.61M | 789.64K | 0 | 0 |
| Net Change in Cash | -1.44M▲ 0% | 3.25M▲ 325.9% | -2.7M▼ 183.0% | 46.55M▲ 1826.7% | -21.46M▼ 146.1% | -15.84M▲ 26.2% | -10.3M▲ 35.0% | 13.72M▲ 233.2% | -10.09M▼ 173.5% |
| Free Cash Flow | -11.37M▲ 0% | -11.83M▼ 4.0% | -11.72M▲ 0.9% | -14M▼ 19.4% | -22.71M▼ 62.3% | -25.45M▼ 12.1% | -33.24M▼ 30.6% | -47.69M▼ 43.5% | -5.88K▲ 100.0% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | -36.06% | -4.05% | 0.92% | -19.43% | -62.27% | -12.06% | -30.62% | -43.46% | 99.99% |
| FCF per Share | -2430.40 | -1197.92 | -458.05 | -211.91 | -122.72 | -108.20 | -81.60 | -38.52 | -0.00 |
| FCF Conversion (FCF/Net Income) | 0.81x | 0.86x | 0.83x | 0.92x | 0.94x | 0.79x | 0.76x | 1.07x | 1.06x |
| Interest Paid | 364 | 0 | 880 | 1.58K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CLRB Key Ratios
Cellectar Biosciences, Inc. (CLRB) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -81.38% | -111.65% | -110.25% | -126.28% | -47.28% | -54.92% | -149.33% | - | -17221.69% | -179.99% |
| Return on Invested Capital (ROIC) | -4395.53% | -693.19% | -2628.14% | - | - | - | - | - | - | - |
| Debt / Equity | 0.01x | 0.00x | 0.00x | 0.06x | 0.01x | 0.01x | 0.06x | - | 0.03x | 0.04x |
| Interest Coverage | -1196.63x | -819.09x | -449.04x | - | - | - | - | - | - | - |
| FCF Conversion | 1.34x | 0.81x | 0.86x | 0.83x | 0.92x | 0.94x | 0.79x | 0.76x | 1.07x | 1.06x |
CLRB Frequently Asked Questions
Cellectar Biosciences, Inc. (CLRB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Cellectar Biosciences, Inc. (CLRB) grew revenue by 0.0% over the past year. Growth has been modest.
Cellectar Biosciences, Inc. (CLRB) reported a net loss of $21.8M for fiscal year 2025.
Dividend & Returns
Cellectar Biosciences, Inc. (CLRB) has a return on equity (ROE) of -180.0%. Negative ROE indicates the company is unprofitable.
Cellectar Biosciences, Inc. (CLRB) had negative free cash flow of $23.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More CLRB
Cellectar Biosciences, Inc. (CLRB) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates